Atlas market file · Etf · United States
ALPS Medical Breakthroughs ETFSBIO
- Last close
- 67.614
- Change
- +0.62%
- 96-bar range
- 47.63 – 69.34
- As of
- 7 Aug 2026
ALPS Medical Breakthroughs ETF is an exchange-traded fund listed as SBIO on AMEX. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
SBIO
Etf · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+82.64% over the window).
Source rail: Yahoo Finance chart API (SBIO). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for SBIO. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
SBIO public profile
Exchange-traded fund. ALPS Medical Breakthroughs ETF is connected to current market context, cited company sources and its retained research file.
ALPS Medical Breakthroughs ETF trades as SBIO on AMEX. ALPS Medical Breakthroughs ETF (SBIO) has a latest verified close of 67.614, up 0.62%, dated 7 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. SBIO stays in the main symbols index until Atlas has enough listing or name evidence for a narrower browse group.
What changed for ALPS Medical Breakthroughs ETF today
The ALPS Medical Breakthroughs ETF (SBIO) is a thematic ETF that aims to provide investors with exposure to companies involved in the development of medical breakthroughs. The fund tracks the ISE Medical Breakthroughs Index, which includes companies engaged in areas like genomics, regenerative medicine, and advanced diagnostics. While the marketing paints a picture of cutting-edge innovation, the reality is that SBIO is a passive fund with a 0.95% expense ratio, holding a basket of stocks that are often volatile and unprofitable.
SBIO's top holdings include biotech firms like Intellia Therapeutics and CRISPR Therapeutics, which are working on gene-editing technologies that could revolutionise medicine. However, these companies are typically pre-revenue or operating at a loss, making them high-risk investments. The fund's tracking method is straightforward-it replicates the performance of the index, rebalancing periodically to stay aligned. This passive approach means the fund doesn't try to pick winners or time the market; it just holds the stocks in the index, providing investors with exposure to the sector's potential but also its risks.
The fund's AUM is around $500 million, with liquidity that is decent but not exceptional. SBIO competes with other healthcare ETFs that offer broader exposure or lower fees, making its thematic appeal a key selling point. However, the fund's 0.95% expense ratio is higher than many of its peers, raising questions about whether the thematic appeal justifies the cost. The fund's performance will ultimately depend on the success of its underlying holdings, which are engaged in high-risk, high-reward research.
SBIO's performance can be tracked on Nasdaq, and its holdings and fees can be analysed using FINRA's Fund Analyzer. The fund's SEC filings provide additional details on its operations and holdings (source: Nasdaq, https://www.nasdaq.com/market-activity/etf/sbio; FINRA Fund Analyzer, https://tools.finra.org/fund_analyzer/; SEC EDGAR, https://www.sec.gov/edgar/search/#/q=SBIO).
Sources & evidence · 3 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
SBIO technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on SBIO
FreedomCore Atlas can expand this public profile into source-led research files with holdings and concentration, index methodology, exposure and overlap, fees and tracking difference, and liquidity context. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep SBIO research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
SBIO FAQ
What is ALPS Medical Breakthroughs ETF (SBIO)?ALPS Medical Breakthroughs ETF (SBIO) has a latest verified close of 67.614, up 0.62%, dated 7 Aug 2026. Use this page to check the price chart, company context,...
ALPS Medical Breakthroughs ETF (SBIO) has a latest verified close of 67.614, up 0.62%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for SBIO?ALPS Medical Breakthroughs ETF (SBIO) has a latest verified close of 67.614, up 0.62%, dated 7 Aug 2026. It brings the latest available chart, company context, cited...
ALPS Medical Breakthroughs ETF (SBIO) has a latest verified close of 67.614, up 0.62%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. SBIO stays in the main symbols index until Atlas has enough listing or name evidence for a narrower browse group.
How often is the SBIO page updated?The SBIO public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The SBIO public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for SBIO?The SBIO file starts with Nasdaq Trader and TradingView AMEX:SBIO. The page separates verified market context from company evidence and shows open evidence gaps instead...
The SBIO file starts with Nasdaq Trader and TradingView AMEX:SBIO. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on SBIO?Yes. The workstation can open SBIO, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open SBIO, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this SBIO page investment advice?No. The SBIO page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The SBIO page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →